mercaptoethyl-3-methyl-3(mercapto)butyramide | 207607-83-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: mercaptoethyl-3-methyl-3(mercapto)butyramide
• 英文别名: 3-methyl-3-sulfanyl-N-(2-sulfanylethyl)butanamide
• CAS: 207607-83-8
• 化学式: C₇H₁₅NOS₂
• 分子量: 193.334
• InChiKey: DOTNGHKPPDWUHN-UHFFFAOYSA-N

物化性质

• 沸点：
  357.0±27.0 °C(Predicted)
• 密度：
  1.085±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  31.1
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  mercaptoethyl-3-methyl-3(mercapto)butyramide 、 1-[-4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以21%的产率得到
  参考文献：
  名称：

  Phosphodiesterase inhibitor compounds and nitric oxide donors

  摘要：

  该发明提供了对男性阳痿、女性性功能障碍和肛门疾病有用的磷酸二酯酶抑制剂和/或一氧化氮供体。

  公开号：

  US20060063774A1
• 作为产物：
  描述：

  mercaptoethyl-3-methyl-3(thioacetyl)butyramide 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 0.08h， 以75%的产率得到mercaptoethyl-3-methyl-3(mercapto)butyramide
  参考文献：
  名称：

  Phosphodiesterase inhibitor compounds and nitric oxide donors

  摘要：

  该发明提供了对男性阳痿、女性性功能障碍和肛门疾病有用的磷酸二酯酶抑制剂和/或一氧化氮供体。

  公开号：

  US20060063774A1

文献信息

• Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith
  申请人：Philippe Michel

  公开号：US20060013784A1

  公开（公告）日：2006-01-19

  The present disclosure relates to specific dimercaptoamides, reducing compositions for permanently reshaping keratin fibers comprising the dimercaptoamides, for instance, human keratin fibers such as the hair; and processes for reshaping keratin fibers comprising the application of said reducing compositions. The present disclosure also relates to processes for preparing the dimercaptoamides.

  本公开涉及特定的二硫代酰胺，用于永久性重塑角蛋白纤维的还原组合物，例如人类角蛋白纤维，如头发；以及包括应用所述还原组合物在内的重塑角蛋白纤维的过程。本公开还涉及制备二硫代酰胺的过程。
• Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
  申请人：——

  公开号：US20030158184A1

  公开（公告）日：2003-08-21

  The invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates, transfers or release nitrogen monoxide, that induces the production of endogenous endothelium-derived relaxing factor, that stimulates endogenous synthesis of nitrogen monoxide, or that is a substrate for nitric oxide synthase. The methods may further comprise administering a therapeutically effective amount of a phosphodiesterase inhibitor and/or a nitrosated and/or nitrosylated phosphodiesterase inhibitor.

  本发明提供了一种通过向女性个体施用至少一种捐赠、转移或释放一氧化氮的化合物，诱导内源性内皮源性松弛因子的产生，刺激内源性一氧化氮的合成，或者是一氧化氮合酶的底物的治疗有效量，来治疗女性性功能障碍的方法。该方法还可以进一步包括施用治疗有效量的磷酸二酯酶抑制剂和/或硝化和/或硝酰化的磷酸二酯酶抑制剂。
• Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use
  申请人：——

  公开号：US20040087591A1

  公开（公告）日：2004-05-06

  The invention describes novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

  该发明描述了一种新型组合物，其中包含至少一种磷酸二酯酶抑制剂，以及至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的化合物。该发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应以及治疗或预防由环磷鸟苷3′，5′-单磷酸（cGMP）代谢增加引起的疾病的方法，如高血压、肺动脉高压、充血性心力衰竭、肾功能衰竭、心肌梗塞、稳定、不稳定和变异性（普林兹梅塔尔）心绞痛、动脉粥样硬化、心脏水肿、肾功能不全、肾病性水肿、肝性水肿、中风、哮喘、支气管炎、慢性阻塞性肺疾病（COPD）、囊性纤维化、痴呆、免疫缺陷、早产、痛经、良性前列腺增生（BPH）、膀胱出口梗阻、失禁、血管通畅度降低的疾病，例如经皮冠状动脉成形术后（post-PTCA）、外周血管疾病、变应性鼻炎、青光眼以及肠道运动障碍等疾病的特征性障碍。
• Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
  申请人：——

  公开号：US20030023087A1

  公开（公告）日：2003-01-30

  The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

  本发明描述了新型的亚硝酸化和/或亚硝基化的磷酸二酯酶抑制剂，以及含有至少一种亚硝酸化和/或亚硝基化的磷酸二酯酶抑制剂和，可选地，一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的化合物的新型组合物。本发明还提供了含有至少一种磷酸二酯酶抑制剂和一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的化合物的新型组合物。本发明还提供了治疗或预防男女性性功能障碍、增强男女性反应、以及治疗或预防由环磷酸鸟苷3',5'-单磷酸（cGMP）代谢增加引起的疾病的方法，如高血压、肺动脉高压、充血性心力衰竭、肾衰竭、心肌梗塞、稳定性、不稳定性和变异性（普林兹梅塔尔）心绞痛、动脉粥样硬化、心脏水肿、肾功能不全、肾病性水肿、肝性水肿、中风、哮喘、支气管炎、慢性阻塞性肺疾病（COPD）、囊性纤维化、痴呆、免疫缺陷、早产、痛经、良性前列腺增生（BPH）、膀胱出口梗阻、失禁、血管通透性降低的疾病，例如经皮冠状动脉成形术后（post-PTCA）、周围血管疾病、过敏性鼻炎、青光眼以及以肠道动力障碍为特征的疾病，例如肠易激综合征（IBS）。
• Utilisation de dimercaptoamides pour la déformation permanente des fibres kératiniques
  申请人：L'OREAL

  公开号：EP1584615A1

  公开（公告）日：2005-10-12

  L'invention concerne l'utilisation, en tant qu'agents réducteurs pour la déformation permanente des fibres kératiniques, et notamment des fibres kératiniques humains telles que les cheveux, de dimercaptoamides particuliers.

  本发明涉及使用特定的二巯基氨基甲酸酯作为还原剂，使角蛋白纤维，特别是人类角蛋白纤维（如头发）永久变形。